Douglas M. Tollefsen

6.0k total citations
94 papers, 5.1k citations indexed

About

Douglas M. Tollefsen is a scholar working on Hematology, Cell Biology and Cancer Research. According to data from OpenAlex, Douglas M. Tollefsen has authored 94 papers receiving a total of 5.1k indexed citations (citations by other indexed papers that have themselves been cited), including 50 papers in Hematology, 45 papers in Cell Biology and 35 papers in Cancer Research. Recurrent topics in Douglas M. Tollefsen's work include Proteoglycans and glycosaminoglycans research (42 papers), Blood Coagulation and Thrombosis Mechanisms (40 papers) and Protease and Inhibitor Mechanisms (33 papers). Douglas M. Tollefsen is often cited by papers focused on Proteoglycans and glycosaminoglycans research (42 papers), Blood Coagulation and Thrombosis Mechanisms (40 papers) and Protease and Inhibitor Mechanisms (33 papers). Douglas M. Tollefsen collaborates with scholars based in United States, Brazil and United Kingdom. Douglas M. Tollefsen's co-authors include Martin Blank, Philip W. Majerus, Margaret M. Maimone, W J Monafo, Li He, Morey A. Blinder, Mauro S.G. Pavão, Paulo A.S. Mourão, John R. Feagler and Cristina Pontes Vicente and has published in prestigious journals such as Journal of the American Chemical Society, Journal of Biological Chemistry and Circulation.

In The Last Decade

Douglas M. Tollefsen

94 papers receiving 4.9k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Douglas M. Tollefsen United States	40	2.3k	1.8k	1.5k	1.5k	494	94	5.1k
Martine Jandrot‐Perrus France	46	3.3k 1.4×	294 0.2×	632 0.4×	1.2k 0.8×	1.2k 2.5×	174	6.1k
Hisao Kato Japan	34	1.4k 0.6×	655 0.4×	384 0.3×	1.9k 1.3×	329 0.7×	135	4.6k
John J. Castellot United States	36	261 0.1×	1.3k 0.7×	746 0.5×	2.3k 1.6×	269 0.5×	77	4.4k
Maurizio Onisto Italy	34	410 0.2×	715 0.4×	1.4k 1.0×	1.6k 1.1×	385 0.8×	87	4.0k
Hidetaro Yasumitsu Japan	36	758 0.3×	342 0.2×	1.2k 0.8×	1.4k 0.9×	109 0.2×	75	3.4k
B Furie United States	36	2.6k 1.2×	434 0.2×	459 0.3×	1.6k 1.1×	473 1.0×	59	5.4k
Chao Niu China	30	1.6k 0.7×	299 0.2×	348 0.2×	1.9k 1.3×	370 0.7×	108	5.0k
Yoshikuni Nagamine Switzerland	44	519 0.2×	443 0.2×	1.5k 1.0×	3.9k 2.7×	200 0.4×	94	5.4k
Françis Belloc France	32	1.3k 0.6×	168 0.1×	350 0.2×	1.6k 1.1×	257 0.5×	118	3.8k
Bernard Le Bonniec France	30	1.2k 0.5×	137 0.1×	511 0.3×	592 0.4×	158 0.3×	79	2.4k

Countries citing papers authored by Douglas M. Tollefsen

Since Specialization

Citations

This map shows the geographic impact of Douglas M. Tollefsen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Douglas M. Tollefsen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Douglas M. Tollefsen more than expected).

Fields of papers citing papers by Douglas M. Tollefsen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Douglas M. Tollefsen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Douglas M. Tollefsen. The network helps show where Douglas M. Tollefsen may publish in the future.

Co-authorship network of co-authors of Douglas M. Tollefsen

This figure shows the co-authorship network connecting the top 25 collaborators of Douglas M. Tollefsen. A scholar is included among the top collaborators of Douglas M. Tollefsen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Douglas M. Tollefsen. Douglas M. Tollefsen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

1.

Marjoram, Robin J., Zhengzhi Li, Li He, et al.. (2014). α2β1 Integrin, GPVI Receptor, and Common FcRγ Chain on Mouse Platelets Mediate Distinct Responses to Collagen in Models of Thrombosis. PLoS ONE. 9(11). e114035–e114035. 26 indexed citations

2.

Kalle, Martina, Praveen Papareddy, Gopinath Kasetty, et al.. (2013). Proteolytic Activation Transforms Heparin Cofactor II into a Host Defense Molecule. The Journal of Immunology. 190(12). 6303–6310. 32 indexed citations

3.

Charles, Julia F., Fabienne Coury, Rosalyn Sulyanto, et al.. (2012). The collection of NFATc1-dependent transcripts in the osteoclast includes numerous genes non-essential to physiologic bone resorption. Bone. 51(5). 902–912. 33 indexed citations

4.

Myerson, Jacob W., He Li, Gregory M. Lanza, Douglas M. Tollefsen, & Samuel A. Wickline. (2011). Abstract 15949: Bivalirudin Nanoparticles Enable Simultaneous Detection and Potent Inhibition of Acute Clotting. Circulation. 124. 1 indexed citations

5.

Tollefsen, Douglas M., et al.. (2011). Dermatan sulfate and bone marrow mononuclear cells used as a new therapeutic strategy after arterial injury in mice. Cytotherapy. 13(6). 695–704. 10 indexed citations

6.

He, Li, Tusar Giri, Cristina Pontes Vicente, & Douglas M. Tollefsen. (2008). Vascular dermatan sulfate regulates the antithrombotic activity of heparin cofactor II. Blood. 111(8). 4118–4125. 44 indexed citations

7.

Werneck, Cláudio C., Cristina Pontes Vicente, Adrian Shifren, et al.. (2008). Mice lacking the extracellular matrix protein MAGP1 display delayed thrombotic occlusion following vessel injury. Blood. 111(8). 4137–4144. 27 indexed citations

8.

He, Li, Cristina Pontes Vicente, Randal J. Westrick, Daniel T. Eitzman, & Douglas M. Tollefsen. (2002). Heparin cofactor II inhibits arterial thrombosis after endothelial injury. Journal of Clinical Investigation. 109(2). 213–219. 90 indexed citations

9.

He, Li, Cristina Pontes Vicente, Randal J. Westrick, Daniel T. Eitzman, & Douglas M. Tollefsen. (2002). Heparin cofactor II inhibits arterial thrombosis after endothelial injury. Journal of Clinical Investigation. 109(2). 213–219. 96 indexed citations

10.

Li, He, Cristina Pontes Vicente, Randal J. Westrick, Daniel T. Eitzman, & Douglas M. Tollefsen. (2002). Heparin cofactor II inhibits arterial thrombosis after endothelial injury. Journal of Clinical Investigation. 109(2). 213–219. 7 indexed citations

11.

Tollefsen, Douglas M.. (2002). Heparin Cofactor II Deficiency. Archives of Pathology & Laboratory Medicine. 126(11). 1394–1400. 39 indexed citations

12.

Deerlin, Vivianna M.D. Van, et al.. (1997). Heparin Facilitates Dissociation of Complexes between Thrombin and a Reactive Site Mutant (L444R) of Heparin Cofactor II. Journal of Biological Chemistry. 272(13). 8243–8249. 14 indexed citations

13.

Colwell, Niall S., Douglas M. Tollefsen, & Morey A. Blinder. (1997). Identification of a Monoclonal Thrombin Inhibitor Associated with Multiple Myeloma and a Severe Bleeding Disorder. British Journal of Haematology. 97(1). 219–226. 33 indexed citations

14.

Deerlin, Vivianna M.D. Van, et al.. (1994). Murine Heparin Cofactor II: Purification, cDNA Sequence, Expression, and Gene Structure. Biochemistry. 33(12). 3632–3642. 20 indexed citations

15.

Gebbink, Raymond Klein, Craig H. Reynolds, Douglas M. Tollefsen, Koen Mertens, & Hans Pannekoek. (1993). Specific glycosaminoglycans support the inhibition of thrombin by plasminogen activator inhibitor 1. Biochemistry. 32(6). 1675–1680. 25 indexed citations

16.

McGuire, Elizabeth A., et al.. (1988). Phosphorylation of vitronectin by a protein kinase in human plasma. Identification of a unique phosphorylation site in the heparin-binding domain.. Journal of Biological Chemistry. 263(4). 1942–1945. 38 indexed citations

17.

Blinder, Morey A., Jayne Marasa, Craig H. Reynolds, Larry L. Deaven, & Douglas M. Tollefsen. (1988). Heparin cofactor II: cDNA sequence, chromosome localization, restriction fragment length polymorphism, and expression in Escherichia coli. Biochemistry. 27(2). 752–759. 63 indexed citations

18.

Tollefsen, Douglas M., et al.. (1982). Heparin cofactor II. Purification and properties of a heparin-dependent inhibitor of thrombin in human plasma.. Journal of Biological Chemistry. 257(5). 2162–2169. 356 indexed citations

19.

Tollefsen, Douglas M. & Philip W. Majerus. (1976). Evidence for a single class of thrombin-binding sites on human platelets. Biochemistry. 15(10). 2144–2149. 58 indexed citations

20.

Tollefsen, Douglas M., John R. Feagler, & Philip W. Majerus. (1974). Induction of the Platelet Release Reaction by Phytohemagglutinin. Journal of Clinical Investigation. 53(1). 211–218. 30 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact